AntibodyTargeted-Drug Conjugates 2015

13-15 April 2015, Crowne Plaza Porto, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Tuesday 14th April 2015

SESSION 5:
CANCER

Moderator: Philip Howard (Spirogen Ltd, London, UK)

09.00-09.30
KEYNOTE:
‘Antibody-drug conjugates for the treatment of cancer’

John A Flygare (Genentech Inc, South San Francisco, California, USA)

09.30-10.00
‘Novel DNA-alkylating agents designed for ADCs’
Victor Goldmacher (ImmunoGen Inc, Waltham, Massachusetts, USA)

10.00-10.30
‘The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers’
Ruud Ubink, Miranda M.C. van der Lee, Patrick Groothuis, Monique A.J. van der Vleuten, Tanja A. van Achterberg, Eline M. Loosveld, Désirée Damming, Daniëlle C.H. Jacobs, Myrthe Rouwette, David F. Egging, Patrick H. Beusker, Peter Goedings, Gijs F.M. Verheijden, Jacques M. Lemmens, C. Marco Timmers and Wim H.A. Dokter (Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands)

10.30-11.00
‘Anti-glycan monoclonal antibodies as candidate drug carriers for cancer treatment’
Mireille Vankemmelbeke, Silvana Tivadar, Jia X. Chua, Richard S. McIntosh, Robert Moss, Tina Parsons, Ian Spendlove and Lindy G. Durrant (University of Nottingham, Nottingham, UK)

11.00-11.30
Coffee Break & Posters

SESSION 6:
PEPTIDES/PROTEINS

Moderator: Michael Firer (Ariel University, Ariel, Israel)

11.30-12.00
‘Phage-derive peptides for use in cancer and immunological diseases’
Michael Firer (Ariel University, Ariel, Israel)

12.00-12.30
‘RG7787- A deimmunised cytolytic fusion protein (cFP): A favourable alternative to ADCs’
Klaus Bosslet (Roche Diagnostics GmbH, Penzberg, Germany)

12.30-13.00
‘Development of novel multifunctional peptide-drugs conjugates for targeted chemotherapy’
Gary Gellerman, Lena Regozin, Boris Redko, Yosi Gilad, Michael Firer and Andrei Bazilevich (Ariel University, Ariel, Israel)

13.00-14.00
Lunch Break & Posters

SESSION 7:
ADC DEVELOPMENT I

Moderator: Roger R. Beerli (NBE-Therapeutics LLC, Basel, Switzerland)

14.00-14.45
‘The role of preclinical cancer models in ADC development: From target identification to predicting clinical response rates’
Hans-Peter Gerber (Pfizer Worldwide R&D, Pearl River, New York, USA)

14.45-15.15
‘Producing better ADCs using ThioBridge™ conjugation’
George Badescu (Abzena PLC, Cambridge, UK)

15.15-15.45
‘Lx, a versatile, water-soluble, platinum-based ADC linker’
Guus A.M.S. van Dongen, Dennis C.J. Waalboer and J.A. Muns (VU University Medical Center, Amsterdam, The Netherlands) and HendrikJan Houthoff and Niels J. Sijbrand (LinXis Pharmaceuticals, Breda, The Netherlands)

15.45-16.15
Tea Break & Posters

SESSION 8:
ADC DEVELOPMENT II

Moderator: Victor Goldmacher (ImmunoGen Inc, Waltham, Massachusetts, USA)

16.15-16.45
‘Improvement of the therapeutic index of amanitin-based ADCs’
Andreas Pahl and Jan Anderl (Heidelberg Pharma GmbH, Ladenburg, Germany)

16.45-17.15
‘The application of site-specific conjugation technology to create novel bispecifics, pegylated biologics and peptide conjugates’
Aaron Sato (Sutro Biopharma Inc., South San Francisco, California, USA)

17.15-17.45
‘Targeting diseases with armed antibodies and small molecule targeted cytotoxics’
Mattia Matasci and Giulio Casi (Philogen AG, Otelfingen, Switzerland)

17.45-18.15
‘ADC targets and payload delivery: Do we know how to select good targets?’
John Lambert (ImmunoGen Inc, Waltham, Massachusetts, USA)

Free Time for ATDC 2015 Delegates

 

ATDC 2015 Sponsors

  • ONdrugDelivery
  • Synthon
  • ADC Review
  • Nascent Biologics
  • Pfizer Oncology
  • Catalent
  • Aldevron
  • Genentech
  • LinXis
  • NBE Therapeutics
  • Biovest
  • DNAvaccine.com
  • ImmunoGen
  • NatureGeneTherapy.com
  • Oncozine
  • Sutro Biopharma

ATDC 2015 Downloads

ATDC 2015 Leaflet

ATDC 2015 Mailing List

Name
E-mail Address
What is 3+2-1?